The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. The REACT (RAD001 Expanded Access Clinical Trial in RCC) study was initiated to address an unmet medical need by providing everolimus prior to commercial availability, and also to further assess the safety and efficacy of everolimus in patients with VEGFr-TKI-refractory mRCC.

Grünwald, V., Karakiewicz, P., Bavbek, S., Miller, K., Machiels, J., Lee, S., et al. (2012). An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. EUROPEAN JOURNAL OF CANCER, 48(3), 324-332 [10.1016/j.ejca.2011.06.054].

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

ROSELLI, MARIO;
2012-02-01

Abstract

The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. The REACT (RAD001 Expanded Access Clinical Trial in RCC) study was initiated to address an unmet medical need by providing everolimus prior to commercial availability, and also to further assess the safety and efficacy of everolimus in patients with VEGFr-TKI-refractory mRCC.
feb-2012
Pubblicato
Rilevanza internazionale
Articolo
Comitato scientifico
Settore MED/06 - ONCOLOGIA MEDICA
English
Con Impact Factor ISI
Sirolimus; Young Adult; Treatment Failure; Antineoplastic Agents; Humans; Aged; Immunosuppressive Agents; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Aged, 80 and over; Kidney Neoplasms; Adult; Carcinoma, Renal Cell; Neoplasm Metastasis; Middle Aged; Female; Male
Grünwald, V., Karakiewicz, P., Bavbek, S., Miller, K., Machiels, J., Lee, S., et al. (2012). An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. EUROPEAN JOURNAL OF CANCER, 48(3), 324-332 [10.1016/j.ejca.2011.06.054].
Grünwald, V; Karakiewicz, P; Bavbek, S; Miller, K; Machiels, J; Lee, S; Larkin, J; Bono, P; Rha, S; Castellano, D; Blank, C; Knox, J; Hawkins, R; Ana...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/100902
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 81
  • ???jsp.display-item.citation.isi??? 73
social impact